391 related articles for article (PubMed ID: 31711626)
1. Targeting Muscarinic Acetylcholine Receptors for the Treatment of Psychiatric and Neurological Disorders.
Moran SP; Maksymetz J; Conn PJ
Trends Pharmacol Sci; 2019 Dec; 40(12):1006-1020. PubMed ID: 31711626
[TBL] [Abstract][Full Text] [Related]
2. Subtype-selective allosteric modulators of muscarinic receptors for the treatment of CNS disorders.
Conn PJ; Jones CK; Lindsley CW
Trends Pharmacol Sci; 2009 Mar; 30(3):148-55. PubMed ID: 19201489
[TBL] [Abstract][Full Text] [Related]
3. Muscarinic acetylcholine receptors as CNS drug targets.
Langmead CJ; Watson J; Reavill C
Pharmacol Ther; 2008 Feb; 117(2):232-43. PubMed ID: 18082893
[TBL] [Abstract][Full Text] [Related]
4. The Muscarinic Acetylcholine Receptor M
Bender AM; Garrison AT; Lindsley CW
ACS Chem Neurosci; 2019 Mar; 10(3):1025-1034. PubMed ID: 30280567
[TBL] [Abstract][Full Text] [Related]
5. Muscarinic receptor pharmacology and circuitry for the modulation of cognition.
Bubser M; Byun N; Wood MR; Jones CK
Handb Exp Pharmacol; 2012; (208):121-66. PubMed ID: 22222698
[TBL] [Abstract][Full Text] [Related]
6. Allosteric activators of muscarinic receptors as novel approaches for treatment of CNS disorders.
Digby GJ; Shirey JK; Conn PJ
Mol Biosyst; 2010 Aug; 6(8):1345-54. PubMed ID: 20582339
[TBL] [Abstract][Full Text] [Related]
7. Muscarinic acetylcholine receptors: mutant mice provide new insights for drug development.
Wess J; Eglen RM; Gautam D
Nat Rev Drug Discov; 2007 Sep; 6(9):721-33. PubMed ID: 17762886
[TBL] [Abstract][Full Text] [Related]
8. Muscarinic acetylcholine receptors for psychotic disorders: bench-side to clinic.
Yohn SE; Weiden PJ; Felder CC; Stahl SM
Trends Pharmacol Sci; 2022 Dec; 43(12):1098-1112. PubMed ID: 36273943
[TBL] [Abstract][Full Text] [Related]
9. Selective allosteric modulation of muscarinic acetylcholine receptors for the treatment of schizophrenia and substance use disorders.
Teal LB; Gould RW; Felts AS; Jones CK
Adv Pharmacol; 2019; 86():153-196. PubMed ID: 31378251
[TBL] [Abstract][Full Text] [Related]
10. Positive allosteric modulation of M
Yohn SE; Conn PJ
Neuropharmacology; 2018 Jul; 136(Pt C):438-448. PubMed ID: 28893562
[TBL] [Abstract][Full Text] [Related]
11. Muscarinic and nicotinic acetylcholine receptor agonists: current scenario in Alzheimer's disease therapy.
Verma S; Kumar A; Tripathi T; Kumar A
J Pharm Pharmacol; 2018 Aug; 70(8):985-993. PubMed ID: 29663387
[TBL] [Abstract][Full Text] [Related]
12. Outline of therapeutic interventions with muscarinic receptor-mediated transmission.
Jakubík J; Šantrůčková E; Randáková A; Janíčková H; Zimčík P; Rudajev V; Michal P; El-Fakahany EE; Doležal V
Physiol Res; 2014; 63(Suppl 1):S177-89. PubMed ID: 24564657
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic opportunities for muscarinic receptors in the central nervous system.
Felder CC; Bymaster FP; Ward J; DeLapp N
J Med Chem; 2000 Nov; 43(23):4333-53. PubMed ID: 11087557
[No Abstract] [Full Text] [Related]
14. Cholinergic muscarinic receptors: new opportunities to treat psychiatric disorders.
Dean B
Future Med Chem; 2013 Sep; 5(13):1547-9. PubMed ID: 24024946
[No Abstract] [Full Text] [Related]
15. New pharmacological approaches to the cholinergic system: an overview on muscarinic receptor ligands and cholinesterase inhibitors.
Greig NH; Reale M; Tata AM
Recent Pat CNS Drug Discov; 2013 Aug; 8(2):123-41. PubMed ID: 23597304
[TBL] [Abstract][Full Text] [Related]
16. M1 muscarinic acetylcholine receptors: A therapeutic strategy for symptomatic and disease-modifying effects in Alzheimer's disease?
Scarpa M; Hesse S; Bradley SJ
Adv Pharmacol; 2020; 88():277-310. PubMed ID: 32416870
[TBL] [Abstract][Full Text] [Related]
17. Allosteric modulation of the M1 muscarinic acetylcholine receptor: improving cognition and a potential treatment for schizophrenia and Alzheimer's disease.
Melancon BJ; Tarr JC; Panarese JD; Wood MR; Lindsley CW
Drug Discov Today; 2013 Dec; 18(23-24):1185-99. PubMed ID: 24051397
[TBL] [Abstract][Full Text] [Related]
18. Muscarinic and nicotinic acetylcholine receptor agonists and allosteric modulators for the treatment of schizophrenia.
Jones CK; Byun N; Bubser M
Neuropsychopharmacology; 2012 Jan; 37(1):16-42. PubMed ID: 21956443
[TBL] [Abstract][Full Text] [Related]
19. Bitopic Binding Mode of an M
Bradley SJ; Molloy C; Bundgaard C; Mogg AJ; Thompson KJ; Dwomoh L; Sanger HE; Crabtree MD; Brooke SM; Sexton PM; Felder CC; Christopoulos A; Broad LM; Tobin AB; Langmead CJ
Mol Pharmacol; 2018 Jun; 93(6):645-656. PubMed ID: 29695609
[TBL] [Abstract][Full Text] [Related]
20. Muscarinic agonists and antagonists in schizophrenia: recent therapeutic advances and future directions.
Bolbecker AR; Shekhar A
Handb Exp Pharmacol; 2012; (208):167-90. PubMed ID: 22222699
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
